Highlights

The organizers are proud to announce that a considerable number of renowned experts in their respective research field will contribute to this Medicinal Chemistry Academy. Attendees will get authentic insights into emerging areas of small-molecule drug discovery, presented by inspiring world-class opinion leaders, some of which are mentioned below. I also have attached a complete overview of the program as it stands today.

Highlights of the 2016 program

  • Prof. Dr. Chas Bountra, Chief Scientist of Oxford’s Structural Genomics Consortium, Professor of Translational Medicine in the Nuffield Department of Clinical Medicine and Associate Member of the Department of Pharmacology at the University of Oxford. Prof. Bountra will introduce into the rapidly changing field of drug discovery targeting epigenetic enzymes and receptor domains.

  • As a world-class expert in Medicinal Chemistry, Dr. Nicholas A. Meanwell, Executive Director at Bristol-Myers Squibb, will provide a detailed report on truly successful drug discovery campaign pursued at BMS that yielded in an innovative HCV drug targeting NS5A, notably Daclatasvir. In addition to reporting on that success story, he will actively teach on the tactical application of bio-isosteric concepts in Lead Finding and Optimization in the course of hands-on tutorials, all attendees will participate in.

  • Dr. Peter Grootenhuis, Senior Director at Vertex Pharmaceuticals, will present a compelling story centered around the discovery and development of a life-changing therapy, namely the Cystis Fibrosis drug Orkambi, consisting of ivacaftor and lumacaftor. This will be a breath-taking medicinal chemistry success story touching upon numerous interdisciplinary aspects such as phenotypic screening and personalized medicine.

  • The detailed aspects of thermodynamics and kinetics involved in the process of molecular recognition will be highlighted by a world-leading specialist in the field of biophysical, crystallographic and computational investigations of drug-target interactions, i.e. Prof. Dr. Gerhard Klebe, Univeristy of Marburg. He will highlight widely under-appreciated optimization parameters the medicinal chemistry community needs to get better acquainted with in the near future. This definitely is a Must-Hear Topic for all practitioners in our scientific research field.

  • The strategic combination of high-resolution crystallography and Fragment-Based Lead Generation applied to one of the most challenging target families, i.e. G Protein-Coupled Receptors, will be introduced by a pioneer in the field, notably Dr. Jonathan Mason, Drug Design and Computational Chemistry Expert at Heptares Therapeutics. He is well known for burning off a firework of structure-based design teachings most relevant for our young colleagues in medicinal chemistry.

  • Prof. Paul Hergenrother, University of Illinois, will introduce the concept of ring-distortion strategies to more efficiently unlock the chemical space around Natural Products for medicinal chemistry applications. This talk will highlight very elegant chemistry approaches towards novel and IP-free scaffolds that can be utilized for library enumeration aiming at natural product-inspired hit structures for subsequent lead finding and optimization campaigns.

 

TPL_BEEZ2_ADDITIONAL_INFORMATION